摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-溴-2-嘧啶甲酸乙酯 | 1197193-30-8

中文名称
5-溴-2-嘧啶甲酸乙酯
中文别名
5-溴嘧啶-2-羧酸甲酯;5-溴-2-嘧啶羧酸乙酯
英文名称
ethyl 5-bromopyrimidine-2-carboxylate
英文别名
——
5-溴-2-嘧啶甲酸乙酯化学式
CAS
1197193-30-8
化学式
C7H7BrN2O2
mdl
——
分子量
231.049
InChiKey
CZQFHUXIWZYQGP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    52.1
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2933599090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335

SDS

SDS:9103ba3a5f9e2e3b6558e69f81b71847
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Ethyl 5-bromopyrimidine-2-carboxylate
Product Name:
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

Section 3. Composition/information on ingredients.
Ethyl 5-bromopyrimidine-2-carboxylate
Ingredient name:
CAS number: 1197193-30-8

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H7BrN2O2
Molecular weight: 231.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] N-(2-(4-((1R,3R)-3-METHYL-2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOL-1-YL)PHENOXY)ETHYL)PROPAN-1-AMINE DERIVATIVES AND RELATED COMPOUNDS AS SELECTIVE DOWN-REGULATORS OF THE ESTROGEN RECEPTOR FOR TREATING CANCER<br/>[FR] DÉRIVÉS N-(2-(4-((1R,3R)-3-MÉTHYL-2,3,4,9-TÉTRAHYDRO-1H-PYRIDO [3,4-B]INDOL-1-YL)PHÉNOXY) ÉTHYL)PROPAN-1-AMINE ET COMPOSÉS ASSOCIÉS EN TANT QUE RÉGULATEURS NÉGATIFS SÉLECTIFS DU RÉCEPTEUR D'OESTROGÈNE POUR LE TRAITEMENT DU CANCER
    申请人:ASTRAZENECA AB
    公开号:WO2018019793A1
    公开(公告)日:2018-02-01
    The specification relates to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, pharmaceutical compositions containing them and to the compounds of Formula (I) for use as selective down-regulators of the estrogen receptor in the treatment of cell proliferative disorders, such as cancer.
    该规范涉及到式(I)的化合物及其药用可接受的盐,用于它们的制备的过程和中间体,含有它们的药物组合物,以及用于作为选择性雌激素受体下调调节剂治疗细胞增殖性疾病(如癌症)的式(I)化合物。
  • CXCR7 ANTAGONISTS
    申请人:ChemoCentryx, Inc.
    公开号:US20140154179A1
    公开(公告)日:2014-06-05
    Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    提供具有化学式I的化合物,或其药用可接受的盐、水合物或N-氧化物,并且这些化合物可用于与CXCR7结合,治疗部分或完全依赖于CXCR7活性的疾病。因此,根据本发明的进一步方面,提供含有上述化合物之一或多个的组合物与药用可接受的赋形剂混合物。
  • [EN] PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRROLOPYRIDAZINE UTILISÉS COMME INHIBITEURS DE KINASE
    申请人:GOSSAMER BIOSERVICES INC
    公开号:WO2022109492A1
    公开(公告)日:2022-05-27
    Described herein are inhibitors of JAK kinases, pharmaceutical compositions comprising them, processes for preparing them and uses of such inhibitors to treat or prevent diseases, disorders and conditions associated with kinase function.
    本文描述了JAK激酶抑制剂,包括它们的制药组合物、制备它们的过程以及使用这些抑制剂来治疗或预防与激酶功能相关的疾病、紊乱和病况。
  • MNK INHIBITORS AND METHODS RELATED THERETO
    申请人:eFFECTOR Therapeutics, Inc.
    公开号:US20160317536A1
    公开(公告)日:2016-11-03
    The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4a , R 4b , R 5 , R 6 , R 7 , R 8 , W 1 , W 2 , Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.
    本发明涉及按照式(I)表示的化合物:或其立体异构体、互变异构体或药学上可接受的盐,其中R1、R2、R3、R4a、R4b、R5、R6、R7、R8、W1、W2、Y和n如本文所定义。还描述了按照式(I)化合物的药学上可接受的组合物,以及利用式(I)化合物和药学上可接受的式(I)化合物组合物作为Mnk抑制剂以及治疗癌症等疾病的治疗剂的方法。
  • ANTIBACTERIAL COMPUNDS
    申请人:Biota Europe Ltd
    公开号:US20150329530A1
    公开(公告)日:2015-11-19
    The present invention provides a compound of the following formula, salts, racemates, diastereomers, enantiomers, esters, carbamates, phosphates, sulfates, deuterated forms and prodrugs thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.
    本发明提供以下式子的化合物,其盐,外消旋体,对映体,酯,氨基甲酸酯,磷酸酯,硫酸酯,氘代形式和前药。此外,还提供这些化合物作为抗菌剂的用途,包含它们的组合物以及它们的制造过程。
查看更多